nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—P-Glycoprotein Inhibitors—Ticagrelor—coronary artery disease	0.328	0.521	CiPCiCtD
Everolimus—Cytochrome P450 3A4 Inhibitors—Ticagrelor—coronary artery disease	0.302	0.479	CiPCiCtD
Everolimus—CYP3A4—Ticagrelor—coronary artery disease	0.0214	0.146	CbGbCtD
Everolimus—CYP3A4—Fenofibrate—coronary artery disease	0.0191	0.131	CbGbCtD
Everolimus—CYP3A4—Gemfibrozil—coronary artery disease	0.0153	0.104	CbGbCtD
Everolimus—CYP3A4—Clopidogrel—coronary artery disease	0.0133	0.0905	CbGbCtD
Everolimus—CYP3A4—Eplerenone—coronary artery disease	0.0123	0.0841	CbGbCtD
Everolimus—CYP3A4—Enalapril—coronary artery disease	0.011	0.075	CbGbCtD
Everolimus—CYP3A4—Rosuvastatin—coronary artery disease	0.00854	0.0583	CbGbCtD
Everolimus—CYP3A4—Ezetimibe—coronary artery disease	0.00854	0.0583	CbGbCtD
Everolimus—CYP3A4—Simvastatin—coronary artery disease	0.00794	0.0542	CbGbCtD
Everolimus—CYP3A4—Pravastatin—coronary artery disease	0.00777	0.053	CbGbCtD
Everolimus—CYP3A4—Lovastatin—coronary artery disease	0.00777	0.053	CbGbCtD
Everolimus—CYP3A4—Atorvastatin—coronary artery disease	0.00708	0.0483	CbGbCtD
Everolimus—CYP3A4—Losartan—coronary artery disease	0.00647	0.0442	CbGbCtD
Everolimus—Sirolimus—FGF2—coronary artery disease	0.00106	0.872	CrCbGaD
Everolimus—Tacrolimus—ALB—coronary artery disease	0.000156	0.128	CrCbGaD
Everolimus—FKBP1A—cardiac ventricle—coronary artery disease	0.000129	0.156	CbGeAlD
Everolimus—FKBP1A—myocardium—coronary artery disease	0.000121	0.147	CbGeAlD
Everolimus—MTOR—heart—coronary artery disease	9.41e-05	0.114	CbGeAlD
Everolimus—MTOR—cardiovascular system—coronary artery disease	8.88e-05	0.108	CbGeAlD
Everolimus—FKBP1A—heart—coronary artery disease	8.46e-05	0.103	CbGeAlD
Everolimus—FKBP1A—cardiovascular system—coronary artery disease	7.98e-05	0.0969	CbGeAlD
Everolimus—FKBP1A—cardiac atrium—coronary artery disease	7.24e-05	0.0879	CbGeAlD
Everolimus—MTOR—blood—coronary artery disease	7.02e-05	0.0852	CbGeAlD
Everolimus—FKBP1A—blood—coronary artery disease	6.31e-05	0.0767	CbGeAlD
Everolimus—Pruritus—Olmesartan—coronary artery disease	2.29e-05	0.00016	CcSEcCtD
Everolimus—Decreased appetite—Losartan—coronary artery disease	2.29e-05	0.00016	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	2.29e-05	0.00016	CcSEcCtD
Everolimus—Abdominal pain—Captopril—coronary artery disease	2.28e-05	0.00016	CcSEcCtD
Everolimus—Body temperature increased—Captopril—coronary artery disease	2.28e-05	0.00016	CcSEcCtD
Everolimus—Dizziness—Simvastatin—coronary artery disease	2.28e-05	0.00016	CcSEcCtD
Everolimus—Rash—Ezetimibe—coronary artery disease	2.28e-05	0.00016	CcSEcCtD
Everolimus—Dermatitis—Ezetimibe—coronary artery disease	2.28e-05	0.000159	CcSEcCtD
Everolimus—Discomfort—Timolol—coronary artery disease	2.27e-05	0.000159	CcSEcCtD
Everolimus—Asthenia—Niacin—coronary artery disease	2.27e-05	0.000159	CcSEcCtD
Everolimus—Fatigue—Losartan—coronary artery disease	2.27e-05	0.000159	CcSEcCtD
Everolimus—Headache—Ezetimibe—coronary artery disease	2.26e-05	0.000158	CcSEcCtD
Everolimus—Malaise—Lisinopril—coronary artery disease	2.26e-05	0.000158	CcSEcCtD
Everolimus—Oedema—Ramipril—coronary artery disease	2.26e-05	0.000158	CcSEcCtD
Everolimus—Dry mouth—Timolol—coronary artery disease	2.25e-05	0.000158	CcSEcCtD
Everolimus—Constipation—Losartan—coronary artery disease	2.25e-05	0.000158	CcSEcCtD
Everolimus—Pain—Losartan—coronary artery disease	2.25e-05	0.000158	CcSEcCtD
Everolimus—Syncope—Lisinopril—coronary artery disease	2.25e-05	0.000157	CcSEcCtD
Everolimus—Vomiting—Eplerenone—coronary artery disease	2.25e-05	0.000157	CcSEcCtD
Everolimus—Feeling abnormal—Furosemide—coronary artery disease	2.25e-05	0.000157	CcSEcCtD
Everolimus—Leukopenia—Lisinopril—coronary artery disease	2.24e-05	0.000157	CcSEcCtD
Everolimus—Nausea—Fenofibrate—coronary artery disease	2.24e-05	0.000157	CcSEcCtD
Everolimus—Pruritus—Niacin—coronary artery disease	2.24e-05	0.000157	CcSEcCtD
Everolimus—Asthenia—Pravastatin—coronary artery disease	2.24e-05	0.000157	CcSEcCtD
Everolimus—Gastrointestinal pain—Furosemide—coronary artery disease	2.23e-05	0.000156	CcSEcCtD
Everolimus—Rash—Eplerenone—coronary artery disease	2.23e-05	0.000156	CcSEcCtD
Everolimus—Hypersensitivity—Trandolapril—coronary artery disease	2.23e-05	0.000156	CcSEcCtD
Everolimus—Dermatitis—Eplerenone—coronary artery disease	2.23e-05	0.000156	CcSEcCtD
Everolimus—Diarrhoea—Valsartan—coronary artery disease	2.23e-05	0.000156	CcSEcCtD
Everolimus—Shock—Ramipril—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Hypersensitivity—Enalapril—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Abdominal pain—Perindopril—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Body temperature increased—Perindopril—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Palpitations—Lisinopril—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Diarrhoea—Olmesartan—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Headache—Eplerenone—coronary artery disease	2.22e-05	0.000155	CcSEcCtD
Everolimus—Nervous system disorder—Ramipril—coronary artery disease	2.21e-05	0.000155	CcSEcCtD
Everolimus—Thrombocytopenia—Ramipril—coronary artery disease	2.21e-05	0.000155	CcSEcCtD
Everolimus—Oedema—Timolol—coronary artery disease	2.21e-05	0.000154	CcSEcCtD
Everolimus—Pruritus—Pravastatin—coronary artery disease	2.2e-05	0.000154	CcSEcCtD
Everolimus—Loss of consciousness—Lisinopril—coronary artery disease	2.2e-05	0.000154	CcSEcCtD
Everolimus—Nausea—Clopidogrel—coronary artery disease	2.2e-05	0.000154	CcSEcCtD
Everolimus—Tachycardia—Ramipril—coronary artery disease	2.2e-05	0.000154	CcSEcCtD
Everolimus—Skin disorder—Ramipril—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Infection—Timolol—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Vomiting—Simvastatin—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Hypersensitivity—Telmisartan—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Cough—Lisinopril—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Nausea—Lovastatin—coronary artery disease	2.19e-05	0.000153	CcSEcCtD
Everolimus—Hyperhidrosis—Ramipril—coronary artery disease	2.18e-05	0.000153	CcSEcCtD
Everolimus—Rash—Simvastatin—coronary artery disease	2.17e-05	0.000152	CcSEcCtD
Everolimus—Dermatitis—Simvastatin—coronary artery disease	2.17e-05	0.000152	CcSEcCtD
Everolimus—Asthenia—Trandolapril—coronary artery disease	2.17e-05	0.000152	CcSEcCtD
Everolimus—Shock—Timolol—coronary artery disease	2.17e-05	0.000152	CcSEcCtD
Everolimus—Feeling abnormal—Losartan—coronary artery disease	2.17e-05	0.000152	CcSEcCtD
Everolimus—Diarrhoea—Niacin—coronary artery disease	2.16e-05	0.000152	CcSEcCtD
Everolimus—Nervous system disorder—Timolol—coronary artery disease	2.16e-05	0.000151	CcSEcCtD
Everolimus—Asthenia—Enalapril—coronary artery disease	2.16e-05	0.000151	CcSEcCtD
Everolimus—Headache—Simvastatin—coronary artery disease	2.16e-05	0.000151	CcSEcCtD
Everolimus—Body temperature increased—Furosemide—coronary artery disease	2.16e-05	0.000151	CcSEcCtD
Everolimus—Abdominal pain—Furosemide—coronary artery disease	2.16e-05	0.000151	CcSEcCtD
Everolimus—Gastrointestinal pain—Losartan—coronary artery disease	2.15e-05	0.000151	CcSEcCtD
Everolimus—Dizziness—Valsartan—coronary artery disease	2.15e-05	0.000151	CcSEcCtD
Everolimus—Anorexia—Ramipril—coronary artery disease	2.15e-05	0.000151	CcSEcCtD
Everolimus—Nausea—Ezetimibe—coronary artery disease	2.15e-05	0.00015	CcSEcCtD
Everolimus—Skin disorder—Timolol—coronary artery disease	2.14e-05	0.00015	CcSEcCtD
Everolimus—Dizziness—Olmesartan—coronary artery disease	2.14e-05	0.00015	CcSEcCtD
Everolimus—Pruritus—Trandolapril—coronary artery disease	2.14e-05	0.00015	CcSEcCtD
Everolimus—Myalgia—Lisinopril—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Arthralgia—Lisinopril—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Chest pain—Lisinopril—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Hyperhidrosis—Timolol—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Asthenia—Telmisartan—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Pruritus—Enalapril—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Diarrhoea—Pravastatin—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Anxiety—Lisinopril—coronary artery disease	2.13e-05	0.000149	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	2.12e-05	0.000148	CcSEcCtD
Everolimus—Discomfort—Lisinopril—coronary artery disease	2.11e-05	0.000148	CcSEcCtD
Everolimus—Hypotension—Ramipril—coronary artery disease	2.11e-05	0.000148	CcSEcCtD
Everolimus—Anorexia—Timolol—coronary artery disease	2.1e-05	0.000147	CcSEcCtD
Everolimus—Pruritus—Telmisartan—coronary artery disease	2.1e-05	0.000147	CcSEcCtD
Everolimus—Nausea—Eplerenone—coronary artery disease	2.1e-05	0.000147	CcSEcCtD
Everolimus—Dizziness—Niacin—coronary artery disease	2.09e-05	0.000146	CcSEcCtD
Everolimus—Dry mouth—Lisinopril—coronary artery disease	2.09e-05	0.000146	CcSEcCtD
Everolimus—Abdominal pain—Losartan—coronary artery disease	2.08e-05	0.000146	CcSEcCtD
Everolimus—Body temperature increased—Losartan—coronary artery disease	2.08e-05	0.000146	CcSEcCtD
Everolimus—Asthenia—Captopril—coronary artery disease	2.07e-05	0.000145	CcSEcCtD
Everolimus—Diarrhoea—Trandolapril—coronary artery disease	2.07e-05	0.000145	CcSEcCtD
Everolimus—Vomiting—Valsartan—coronary artery disease	2.07e-05	0.000145	CcSEcCtD
Everolimus—CYP3A4—blood—coronary artery disease	2.06e-05	0.025	CbGeAlD
Everolimus—Diarrhoea—Enalapril—coronary artery disease	2.06e-05	0.000144	CcSEcCtD
Everolimus—Hypotension—Timolol—coronary artery disease	2.06e-05	0.000144	CcSEcCtD
Everolimus—Dizziness—Pravastatin—coronary artery disease	2.06e-05	0.000144	CcSEcCtD
Everolimus—Vomiting—Olmesartan—coronary artery disease	2.06e-05	0.000144	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Ramipril—coronary artery disease	2.06e-05	0.000144	CcSEcCtD
Everolimus—Rash—Valsartan—coronary artery disease	2.05e-05	0.000144	CcSEcCtD
Everolimus—Dermatitis—Valsartan—coronary artery disease	2.05e-05	0.000144	CcSEcCtD
Everolimus—Nausea—Simvastatin—coronary artery disease	2.05e-05	0.000143	CcSEcCtD
Everolimus—Oedema—Lisinopril—coronary artery disease	2.05e-05	0.000143	CcSEcCtD
Everolimus—Pruritus—Captopril—coronary artery disease	2.04e-05	0.000143	CcSEcCtD
Everolimus—Rash—Olmesartan—coronary artery disease	2.04e-05	0.000143	CcSEcCtD
Everolimus—Insomnia—Ramipril—coronary artery disease	2.04e-05	0.000143	CcSEcCtD
Everolimus—Dermatitis—Olmesartan—coronary artery disease	2.04e-05	0.000143	CcSEcCtD
Everolimus—Headache—Valsartan—coronary artery disease	2.04e-05	0.000143	CcSEcCtD
Everolimus—Diarrhoea—Telmisartan—coronary artery disease	2.03e-05	0.000142	CcSEcCtD
Everolimus—Infection—Lisinopril—coronary artery disease	2.03e-05	0.000142	CcSEcCtD
Everolimus—Headache—Olmesartan—coronary artery disease	2.03e-05	0.000142	CcSEcCtD
Everolimus—Paraesthesia—Ramipril—coronary artery disease	2.03e-05	0.000142	CcSEcCtD
Everolimus—Shock—Lisinopril—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Asthenia—Perindopril—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Dyspnoea—Ramipril—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Vomiting—Niacin—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Timolol—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Hypersensitivity—Furosemide—coronary artery disease	2.01e-05	0.000141	CcSEcCtD
Everolimus—Somnolence—Ramipril—coronary artery disease	2.01e-05	0.00014	CcSEcCtD
Everolimus—Thrombocytopenia—Lisinopril—coronary artery disease	2e-05	0.00014	CcSEcCtD
Everolimus—Dizziness—Trandolapril—coronary artery disease	2e-05	0.00014	CcSEcCtD
Everolimus—Tachycardia—Lisinopril—coronary artery disease	2e-05	0.00014	CcSEcCtD
Everolimus—Insomnia—Timolol—coronary artery disease	2e-05	0.00014	CcSEcCtD
Everolimus—Rash—Niacin—coronary artery disease	2e-05	0.00014	CcSEcCtD
Everolimus—Dermatitis—Niacin—coronary artery disease	1.99e-05	0.00014	CcSEcCtD
Everolimus—Dizziness—Enalapril—coronary artery disease	1.99e-05	0.00014	CcSEcCtD
Everolimus—Skin disorder—Lisinopril—coronary artery disease	1.99e-05	0.000139	CcSEcCtD
Everolimus—Dyspepsia—Ramipril—coronary artery disease	1.99e-05	0.000139	CcSEcCtD
Everolimus—Pruritus—Perindopril—coronary artery disease	1.99e-05	0.000139	CcSEcCtD
Everolimus—Headache—Niacin—coronary artery disease	1.98e-05	0.000139	CcSEcCtD
Everolimus—Paraesthesia—Timolol—coronary artery disease	1.98e-05	0.000139	CcSEcCtD
Everolimus—Vomiting—Pravastatin—coronary artery disease	1.98e-05	0.000139	CcSEcCtD
Everolimus—Hyperhidrosis—Lisinopril—coronary artery disease	1.98e-05	0.000139	CcSEcCtD
Everolimus—Diarrhoea—Captopril—coronary artery disease	1.98e-05	0.000138	CcSEcCtD
Everolimus—Dyspnoea—Timolol—coronary artery disease	1.97e-05	0.000138	CcSEcCtD
Everolimus—Dizziness—Telmisartan—coronary artery disease	1.97e-05	0.000138	CcSEcCtD
Everolimus—Rash—Pravastatin—coronary artery disease	1.96e-05	0.000138	CcSEcCtD
Everolimus—Dermatitis—Pravastatin—coronary artery disease	1.96e-05	0.000137	CcSEcCtD
Everolimus—Decreased appetite—Ramipril—coronary artery disease	1.96e-05	0.000137	CcSEcCtD
Everolimus—Somnolence—Timolol—coronary artery disease	1.96e-05	0.000137	CcSEcCtD
Everolimus—Asthenia—Furosemide—coronary artery disease	1.96e-05	0.000137	CcSEcCtD
Everolimus—Headache—Pravastatin—coronary artery disease	1.95e-05	0.000137	CcSEcCtD
Everolimus—Anorexia—Lisinopril—coronary artery disease	1.95e-05	0.000137	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ramipril—coronary artery disease	1.95e-05	0.000136	CcSEcCtD
Everolimus—Fatigue—Ramipril—coronary artery disease	1.95e-05	0.000136	CcSEcCtD
Everolimus—Dyspepsia—Timolol—coronary artery disease	1.94e-05	0.000136	CcSEcCtD
Everolimus—Hypersensitivity—Losartan—coronary artery disease	1.94e-05	0.000136	CcSEcCtD
Everolimus—Nausea—Valsartan—coronary artery disease	1.93e-05	0.000135	CcSEcCtD
Everolimus—Pruritus—Furosemide—coronary artery disease	1.93e-05	0.000135	CcSEcCtD
Everolimus—Constipation—Ramipril—coronary artery disease	1.93e-05	0.000135	CcSEcCtD
Everolimus—Nausea—Olmesartan—coronary artery disease	1.92e-05	0.000135	CcSEcCtD
Everolimus—Vomiting—Trandolapril—coronary artery disease	1.92e-05	0.000135	CcSEcCtD
Everolimus—Diarrhoea—Perindopril—coronary artery disease	1.92e-05	0.000134	CcSEcCtD
Everolimus—Decreased appetite—Timolol—coronary artery disease	1.92e-05	0.000134	CcSEcCtD
Everolimus—Vomiting—Enalapril—coronary artery disease	1.92e-05	0.000134	CcSEcCtD
Everolimus—Hypotension—Lisinopril—coronary artery disease	1.91e-05	0.000134	CcSEcCtD
Everolimus—Dizziness—Captopril—coronary artery disease	1.91e-05	0.000134	CcSEcCtD
Everolimus—Rash—Trandolapril—coronary artery disease	1.91e-05	0.000134	CcSEcCtD
Everolimus—Dermatitis—Trandolapril—coronary artery disease	1.91e-05	0.000133	CcSEcCtD
Everolimus—Gastrointestinal disorder—Timolol—coronary artery disease	1.9e-05	0.000133	CcSEcCtD
Everolimus—Fatigue—Timolol—coronary artery disease	1.9e-05	0.000133	CcSEcCtD
Everolimus—Rash—Enalapril—coronary artery disease	1.9e-05	0.000133	CcSEcCtD
Everolimus—Dermatitis—Enalapril—coronary artery disease	1.9e-05	0.000133	CcSEcCtD
Everolimus—Headache—Trandolapril—coronary artery disease	1.9e-05	0.000133	CcSEcCtD
Everolimus—Vomiting—Telmisartan—coronary artery disease	1.89e-05	0.000132	CcSEcCtD
Everolimus—Asthenia—Losartan—coronary artery disease	1.89e-05	0.000132	CcSEcCtD
Everolimus—Headache—Enalapril—coronary artery disease	1.89e-05	0.000132	CcSEcCtD
Everolimus—Pain—Timolol—coronary artery disease	1.89e-05	0.000132	CcSEcCtD
Everolimus—Nausea—Niacin—coronary artery disease	1.88e-05	0.000132	CcSEcCtD
Everolimus—Rash—Telmisartan—coronary artery disease	1.87e-05	0.000131	CcSEcCtD
Everolimus—Dermatitis—Telmisartan—coronary artery disease	1.87e-05	0.000131	CcSEcCtD
Everolimus—Diarrhoea—Furosemide—coronary artery disease	1.87e-05	0.000131	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Lisinopril—coronary artery disease	1.86e-05	0.000131	CcSEcCtD
Everolimus—Pruritus—Losartan—coronary artery disease	1.86e-05	0.00013	CcSEcCtD
Everolimus—Headache—Telmisartan—coronary artery disease	1.86e-05	0.00013	CcSEcCtD
Everolimus—Feeling abnormal—Ramipril—coronary artery disease	1.86e-05	0.00013	CcSEcCtD
Everolimus—Dizziness—Perindopril—coronary artery disease	1.86e-05	0.00013	CcSEcCtD
Everolimus—Insomnia—Lisinopril—coronary artery disease	1.85e-05	0.00013	CcSEcCtD
Everolimus—Nausea—Pravastatin—coronary artery disease	1.85e-05	0.00013	CcSEcCtD
Everolimus—Gastrointestinal pain—Ramipril—coronary artery disease	1.85e-05	0.000129	CcSEcCtD
Everolimus—Paraesthesia—Lisinopril—coronary artery disease	1.84e-05	0.000129	CcSEcCtD
Everolimus—Vomiting—Captopril—coronary artery disease	1.84e-05	0.000129	CcSEcCtD
Everolimus—Dyspnoea—Lisinopril—coronary artery disease	1.82e-05	0.000128	CcSEcCtD
Everolimus—Rash—Captopril—coronary artery disease	1.82e-05	0.000128	CcSEcCtD
Everolimus—Dermatitis—Captopril—coronary artery disease	1.82e-05	0.000127	CcSEcCtD
Everolimus—Somnolence—Lisinopril—coronary artery disease	1.82e-05	0.000127	CcSEcCtD
Everolimus—Feeling abnormal—Timolol—coronary artery disease	1.82e-05	0.000127	CcSEcCtD
Everolimus—Headache—Captopril—coronary artery disease	1.81e-05	0.000127	CcSEcCtD
Everolimus—Gastrointestinal pain—Timolol—coronary artery disease	1.8e-05	0.000126	CcSEcCtD
Everolimus—Dizziness—Furosemide—coronary artery disease	1.8e-05	0.000126	CcSEcCtD
Everolimus—Dyspepsia—Lisinopril—coronary artery disease	1.8e-05	0.000126	CcSEcCtD
Everolimus—Diarrhoea—Losartan—coronary artery disease	1.8e-05	0.000126	CcSEcCtD
Everolimus—Nausea—Trandolapril—coronary artery disease	1.8e-05	0.000126	CcSEcCtD
Everolimus—Nausea—Enalapril—coronary artery disease	1.79e-05	0.000125	CcSEcCtD
Everolimus—Vomiting—Perindopril—coronary artery disease	1.78e-05	0.000125	CcSEcCtD
Everolimus—Abdominal pain—Ramipril—coronary artery disease	1.78e-05	0.000125	CcSEcCtD
Everolimus—Body temperature increased—Ramipril—coronary artery disease	1.78e-05	0.000125	CcSEcCtD
Everolimus—Decreased appetite—Lisinopril—coronary artery disease	1.78e-05	0.000125	CcSEcCtD
Everolimus—Rash—Perindopril—coronary artery disease	1.77e-05	0.000124	CcSEcCtD
Everolimus—Dermatitis—Perindopril—coronary artery disease	1.77e-05	0.000124	CcSEcCtD
Everolimus—Gastrointestinal disorder—Lisinopril—coronary artery disease	1.77e-05	0.000124	CcSEcCtD
Everolimus—Nausea—Telmisartan—coronary artery disease	1.77e-05	0.000124	CcSEcCtD
Everolimus—Fatigue—Lisinopril—coronary artery disease	1.76e-05	0.000124	CcSEcCtD
Everolimus—Headache—Perindopril—coronary artery disease	1.76e-05	0.000123	CcSEcCtD
Everolimus—Pain—Lisinopril—coronary artery disease	1.75e-05	0.000123	CcSEcCtD
Everolimus—Constipation—Lisinopril—coronary artery disease	1.75e-05	0.000123	CcSEcCtD
Everolimus—Body temperature increased—Timolol—coronary artery disease	1.74e-05	0.000122	CcSEcCtD
Everolimus—Abdominal pain—Timolol—coronary artery disease	1.74e-05	0.000122	CcSEcCtD
Everolimus—Dizziness—Losartan—coronary artery disease	1.74e-05	0.000122	CcSEcCtD
Everolimus—Vomiting—Furosemide—coronary artery disease	1.73e-05	0.000121	CcSEcCtD
Everolimus—Rash—Furosemide—coronary artery disease	1.72e-05	0.00012	CcSEcCtD
Everolimus—Dermatitis—Furosemide—coronary artery disease	1.72e-05	0.00012	CcSEcCtD
Everolimus—Nausea—Captopril—coronary artery disease	1.72e-05	0.00012	CcSEcCtD
Everolimus—Headache—Furosemide—coronary artery disease	1.71e-05	0.00012	CcSEcCtD
Everolimus—Feeling abnormal—Lisinopril—coronary artery disease	1.69e-05	0.000118	CcSEcCtD
Everolimus—Gastrointestinal pain—Lisinopril—coronary artery disease	1.67e-05	0.000117	CcSEcCtD
Everolimus—Vomiting—Losartan—coronary artery disease	1.67e-05	0.000117	CcSEcCtD
Everolimus—Nausea—Perindopril—coronary artery disease	1.67e-05	0.000117	CcSEcCtD
Everolimus—Hypersensitivity—Ramipril—coronary artery disease	1.66e-05	0.000116	CcSEcCtD
Everolimus—Rash—Losartan—coronary artery disease	1.66e-05	0.000116	CcSEcCtD
Everolimus—Dermatitis—Losartan—coronary artery disease	1.66e-05	0.000116	CcSEcCtD
Everolimus—Headache—Losartan—coronary artery disease	1.65e-05	0.000115	CcSEcCtD
Everolimus—Hypersensitivity—Timolol—coronary artery disease	1.63e-05	0.000114	CcSEcCtD
Everolimus—Nausea—Furosemide—coronary artery disease	1.62e-05	0.000113	CcSEcCtD
Everolimus—Asthenia—Ramipril—coronary artery disease	1.62e-05	0.000113	CcSEcCtD
Everolimus—Abdominal pain—Lisinopril—coronary artery disease	1.62e-05	0.000113	CcSEcCtD
Everolimus—Body temperature increased—Lisinopril—coronary artery disease	1.62e-05	0.000113	CcSEcCtD
Everolimus—Pruritus—Ramipril—coronary artery disease	1.6e-05	0.000112	CcSEcCtD
Everolimus—Asthenia—Timolol—coronary artery disease	1.58e-05	0.000111	CcSEcCtD
Everolimus—Nausea—Losartan—coronary artery disease	1.56e-05	0.000109	CcSEcCtD
Everolimus—Pruritus—Timolol—coronary artery disease	1.56e-05	0.000109	CcSEcCtD
Everolimus—Diarrhoea—Ramipril—coronary artery disease	1.54e-05	0.000108	CcSEcCtD
Everolimus—Diarrhoea—Timolol—coronary artery disease	1.51e-05	0.000106	CcSEcCtD
Everolimus—Hypersensitivity—Lisinopril—coronary artery disease	1.51e-05	0.000106	CcSEcCtD
Everolimus—Dizziness—Ramipril—coronary artery disease	1.49e-05	0.000104	CcSEcCtD
Everolimus—Asthenia—Lisinopril—coronary artery disease	1.47e-05	0.000103	CcSEcCtD
Everolimus—Dizziness—Timolol—coronary artery disease	1.46e-05	0.000102	CcSEcCtD
Everolimus—Pruritus—Lisinopril—coronary artery disease	1.45e-05	0.000101	CcSEcCtD
Everolimus—Vomiting—Ramipril—coronary artery disease	1.43e-05	0.0001	CcSEcCtD
Everolimus—Rash—Ramipril—coronary artery disease	1.42e-05	9.96e-05	CcSEcCtD
Everolimus—Dermatitis—Ramipril—coronary artery disease	1.42e-05	9.95e-05	CcSEcCtD
Everolimus—Headache—Ramipril—coronary artery disease	1.41e-05	9.9e-05	CcSEcCtD
Everolimus—Vomiting—Timolol—coronary artery disease	1.4e-05	9.82e-05	CcSEcCtD
Everolimus—Diarrhoea—Lisinopril—coronary artery disease	1.4e-05	9.8e-05	CcSEcCtD
Everolimus—Rash—Timolol—coronary artery disease	1.39e-05	9.74e-05	CcSEcCtD
Everolimus—Dermatitis—Timolol—coronary artery disease	1.39e-05	9.73e-05	CcSEcCtD
Everolimus—Headache—Timolol—coronary artery disease	1.38e-05	9.68e-05	CcSEcCtD
Everolimus—Dizziness—Lisinopril—coronary artery disease	1.35e-05	9.48e-05	CcSEcCtD
Everolimus—Nausea—Ramipril—coronary artery disease	1.34e-05	9.39e-05	CcSEcCtD
Everolimus—Nausea—Timolol—coronary artery disease	1.31e-05	9.18e-05	CcSEcCtD
Everolimus—Vomiting—Lisinopril—coronary artery disease	1.3e-05	9.11e-05	CcSEcCtD
Everolimus—Rash—Lisinopril—coronary artery disease	1.29e-05	9.04e-05	CcSEcCtD
Everolimus—Dermatitis—Lisinopril—coronary artery disease	1.29e-05	9.03e-05	CcSEcCtD
Everolimus—Headache—Lisinopril—coronary artery disease	1.28e-05	8.98e-05	CcSEcCtD
Everolimus—Nausea—Lisinopril—coronary artery disease	1.22e-05	8.51e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—EDNRA—coronary artery disease	6.93e-06	8.76e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—LPL—coronary artery disease	6.92e-06	8.75e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCD—coronary artery disease	6.9e-06	8.73e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB1—coronary artery disease	6.89e-06	8.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CYBA—coronary artery disease	6.89e-06	8.72e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—coronary artery disease	6.89e-06	8.72e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DUSP6—coronary artery disease	6.86e-06	8.69e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FN1—coronary artery disease	6.81e-06	8.61e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—coronary artery disease	6.81e-06	8.61e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6ST—coronary artery disease	6.78e-06	8.58e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLAT—coronary artery disease	6.75e-06	8.54e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—coronary artery disease	6.74e-06	8.54e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKBIA—coronary artery disease	6.73e-06	8.51e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIT—coronary artery disease	6.51e-06	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL12—coronary artery disease	6.51e-06	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BDKRB2—coronary artery disease	6.51e-06	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—coronary artery disease	6.51e-06	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP2CA—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CKMT2—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PDK4—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SULT4A1—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH6A1—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PYGM—coronary artery disease	6.49e-06	8.21e-05	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—coronary artery disease	6.47e-06	8.19e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—coronary artery disease	6.46e-06	8.17e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—coronary artery disease	6.42e-06	8.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUNB—coronary artery disease	6.39e-06	8.09e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCD—coronary artery disease	6.37e-06	8.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLCB1—coronary artery disease	6.37e-06	8.06e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GSK3B—coronary artery disease	6.25e-06	7.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR7—coronary artery disease	6.24e-06	7.89e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—coronary artery disease	6.23e-06	7.88e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—coronary artery disease	6.2e-06	7.85e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CREB1—coronary artery disease	6.2e-06	7.85e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK14—coronary artery disease	6.11e-06	7.73e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—coronary artery disease	6.07e-06	7.68e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6R—coronary artery disease	6.05e-06	7.65e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—coronary artery disease	5.96e-06	7.55e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ITGAV—coronary artery disease	5.94e-06	7.52e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—coronary artery disease	5.94e-06	7.52e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KNG1—coronary artery disease	5.92e-06	7.5e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—coronary artery disease	5.9e-06	7.46e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6ST—coronary artery disease	5.9e-06	7.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—coronary artery disease	5.89e-06	7.45e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKBIA—coronary artery disease	5.85e-06	7.4e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—coronary artery disease	5.8e-06	7.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMGCS2—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GYG1—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GK—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LDHA—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PFKM—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GATM—coronary artery disease	5.78e-06	7.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL10—coronary artery disease	5.75e-06	7.28e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLG—coronary artery disease	5.74e-06	7.26e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—coronary artery disease	5.73e-06	7.25e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—coronary artery disease	5.67e-06	7.17e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—coronary artery disease	5.66e-06	7.17e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—coronary artery disease	5.59e-06	7.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AK1—coronary artery disease	5.52e-06	6.98e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCH1—coronary artery disease	5.52e-06	6.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCE—coronary artery disease	5.52e-06	6.98e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS1—coronary artery disease	5.5e-06	6.96e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—S100B—coronary artery disease	5.49e-06	6.94e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF2—coronary artery disease	5.48e-06	6.94e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6ST—coronary artery disease	5.45e-06	6.89e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—GSK3B—coronary artery disease	5.44e-06	6.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS3—coronary artery disease	5.43e-06	6.88e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—coronary artery disease	5.41e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—coronary artery disease	5.4e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREB1—coronary artery disease	5.39e-06	6.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KITLG—coronary artery disease	5.37e-06	6.79e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFBR2—coronary artery disease	5.37e-06	6.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCD1—coronary artery disease	5.29e-06	6.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UGCG—coronary artery disease	5.29e-06	6.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MDH2—coronary artery disease	5.29e-06	6.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPAT—coronary artery disease	5.29e-06	6.69e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6R—coronary artery disease	5.26e-06	6.66e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JAK2—coronary artery disease	5.26e-06	6.65e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT5A—coronary artery disease	5.25e-06	6.64e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP3—coronary artery disease	5.25e-06	6.64e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK1—coronary artery disease	5.24e-06	6.63e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—coronary artery disease	5.23e-06	6.62e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—coronary artery disease	5.11e-06	6.46e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PGM1—coronary artery disease	5.09e-06	6.44e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOB—coronary artery disease	5.07e-06	6.42e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—GSK3B—coronary artery disease	5.02e-06	6.35e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MAPK1—coronary artery disease	5.01e-06	6.34e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—coronary artery disease	4.99e-06	6.32e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CREB1—coronary artery disease	4.98e-06	6.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL5—coronary artery disease	4.95e-06	6.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PYGB—coronary artery disease	4.92e-06	6.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CKB—coronary artery disease	4.92e-06	6.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF1—coronary artery disease	4.88e-06	6.17e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—coronary artery disease	4.88e-06	6.17e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6R—coronary artery disease	4.86e-06	6.15e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—coronary artery disease	4.84e-06	6.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RPS6KB1—coronary artery disease	4.8e-06	6.07e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MEF2C—coronary artery disease	4.8e-06	6.07e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—coronary artery disease	4.8e-06	6.07e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF2—coronary artery disease	4.77e-06	6.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ITGB3—coronary artery disease	4.68e-06	5.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM2—coronary artery disease	4.62e-06	5.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DLAT—coronary artery disease	4.62e-06	5.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COX5B—coronary artery disease	4.62e-06	5.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLIN1—coronary artery disease	4.62e-06	5.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PFKFB3—coronary artery disease	4.62e-06	5.85e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—coronary artery disease	4.59e-06	5.81e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JAK2—coronary artery disease	4.57e-06	5.79e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—coronary artery disease	4.55e-06	5.76e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—coronary artery disease	4.54e-06	5.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP2CA—coronary artery disease	4.54e-06	5.75e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—coronary artery disease	4.53e-06	5.73e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—coronary artery disease	4.47e-06	5.66e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCD—coronary artery disease	4.46e-06	5.65e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF2—coronary artery disease	4.4e-06	5.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SULT1E1—coronary artery disease	4.38e-06	5.55e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2A—coronary artery disease	4.37e-06	5.53e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—coronary artery disease	4.36e-06	5.52e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—coronary artery disease	4.36e-06	5.52e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—coronary artery disease	4.35e-06	5.5e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—coronary artery disease	4.34e-06	5.5e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—coronary artery disease	4.34e-06	5.49e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—JAK2—coronary artery disease	4.22e-06	5.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1B1—coronary artery disease	4.18e-06	5.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HK2—coronary artery disease	4.18e-06	5.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—coronary artery disease	4.16e-06	5.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—coronary artery disease	4.14e-06	5.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—coronary artery disease	4.06e-06	5.14e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—coronary artery disease	4.06e-06	5.14e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—coronary artery disease	4.02e-06	5.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—coronary artery disease	4.01e-06	5.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC27A1—coronary artery disease	4.01e-06	5.07e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—coronary artery disease	4e-06	5.07e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—coronary artery disease	3.98e-06	5.03e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—coronary artery disease	3.97e-06	5.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK14—coronary artery disease	3.95e-06	5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CPT1B—coronary artery disease	3.93e-06	4.98e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LCAT—coronary artery disease	3.93e-06	4.98e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—coronary artery disease	3.9e-06	4.93e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—coronary artery disease	3.88e-06	4.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA4—coronary artery disease	3.86e-06	4.88e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—coronary artery disease	3.85e-06	4.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—coronary artery disease	3.83e-06	4.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FN1—coronary artery disease	3.83e-06	4.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6ST—coronary artery disease	3.81e-06	4.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKBIA—coronary artery disease	3.78e-06	4.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PDHA1—coronary artery disease	3.73e-06	4.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCLM—coronary artery disease	3.73e-06	4.72e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—coronary artery disease	3.71e-06	4.7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—coronary artery disease	3.66e-06	4.64e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP11B2—coronary artery disease	3.61e-06	4.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TXNRD1—coronary artery disease	3.61e-06	4.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—coronary artery disease	3.58e-06	4.53e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—coronary artery disease	3.57e-06	4.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC22A3—coronary artery disease	3.56e-06	4.5e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—coronary artery disease	3.55e-06	4.49e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GSK3B—coronary artery disease	3.52e-06	4.45e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK1—coronary artery disease	3.51e-06	4.44e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HADH—coronary artery disease	3.5e-06	4.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ARNTL—coronary artery disease	3.5e-06	4.43e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—coronary artery disease	3.49e-06	4.41e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREB1—coronary artery disease	3.49e-06	4.41e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—coronary artery disease	3.41e-06	4.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6R—coronary artery disease	3.4e-06	4.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—coronary artery disease	3.35e-06	4.25e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA2—coronary artery disease	3.32e-06	4.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G2A—coronary artery disease	3.32e-06	4.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX2—coronary artery disease	3.32e-06	4.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG5—coronary artery disease	3.28e-06	4.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX4—coronary artery disease	3.28e-06	4.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SULT1A1—coronary artery disease	3.28e-06	4.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HK1—coronary artery disease	3.28e-06	4.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HADHA—coronary artery disease	3.24e-06	4.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA1—coronary artery disease	3.21e-06	4.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—coronary artery disease	3.19e-06	4.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPA—coronary artery disease	3.17e-06	4.01e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—coronary artery disease	3.08e-06	3.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCB3—coronary artery disease	3.07e-06	3.88e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK1—coronary artery disease	3.05e-06	3.86e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—coronary artery disease	3.04e-06	3.85e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—coronary artery disease	3.04e-06	3.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA5—coronary artery disease	3.04e-06	3.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—P4HB—coronary artery disease	2.98e-06	3.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAK2—coronary artery disease	2.96e-06	3.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	2.92e-06	3.7e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—coronary artery disease	2.87e-06	3.63e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MAPK1—coronary artery disease	2.82e-06	3.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—VCAN—coronary artery disease	2.76e-06	3.49e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOA—coronary artery disease	2.74e-06	3.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—coronary artery disease	2.7e-06	3.41e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—coronary artery disease	2.69e-06	3.41e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DCN—coronary artery disease	2.66e-06	3.36e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—coronary artery disease	2.65e-06	3.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH2—coronary artery disease	2.58e-06	3.27e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—coronary artery disease	2.58e-06	3.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPC—coronary artery disease	2.52e-06	3.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HBA1—coronary artery disease	2.52e-06	3.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	2.52e-06	3.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2C19—coronary artery disease	2.52e-06	3.19e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—coronary artery disease	2.51e-06	3.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOC3—coronary artery disease	2.5e-06	3.17e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LDLR—coronary artery disease	2.49e-06	3.15e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—coronary artery disease	2.49e-06	3.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC9A1—coronary artery disease	2.46e-06	3.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTT1—coronary artery disease	2.46e-06	3.11e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—coronary artery disease	2.44e-06	3.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—coronary artery disease	2.44e-06	3.09e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCLC—coronary artery disease	2.43e-06	3.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CETP—coronary artery disease	2.43e-06	3.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDC1—coronary artery disease	2.4e-06	3.04e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—coronary artery disease	2.34e-06	2.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMB5—coronary artery disease	2.27e-06	2.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMA6—coronary artery disease	2.27e-06	2.87e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CTGF—coronary artery disease	2.22e-06	2.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT2—coronary artery disease	2.2e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMGCR—coronary artery disease	2.2e-06	2.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—coronary artery disease	2.19e-06	2.77e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—coronary artery disease	2.16e-06	2.74e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—coronary artery disease	2.16e-06	2.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCB1—coronary artery disease	2.02e-06	2.56e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—coronary artery disease	2.01e-06	2.55e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—coronary artery disease	2e-06	2.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK1—coronary artery disease	1.97e-06	2.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCA1—coronary artery disease	1.96e-06	2.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GGT1—coronary artery disease	1.9e-06	2.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT1—coronary artery disease	1.9e-06	2.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—coronary artery disease	1.71e-06	2.17e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—coronary artery disease	1.7e-06	2.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	1.69e-06	2.14e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—coronary artery disease	1.68e-06	2.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—coronary artery disease	1.66e-06	2.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOB—coronary artery disease	1.61e-06	2.04e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—coronary artery disease	1.57e-06	1.98e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—coronary artery disease	1.54e-06	1.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—coronary artery disease	1.52e-06	1.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—coronary artery disease	1.5e-06	1.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—coronary artery disease	1.46e-06	1.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2CA—coronary artery disease	1.44e-06	1.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—coronary artery disease	1.4e-06	1.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—coronary artery disease	1.38e-06	1.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—coronary artery disease	1.31e-06	1.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—coronary artery disease	1.29e-06	1.63e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—coronary artery disease	1.27e-06	1.61e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—coronary artery disease	1.12e-06	1.42e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—coronary artery disease	1.11e-06	1.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—coronary artery disease	1.01e-06	1.28e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—coronary artery disease	9.65e-07	1.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—coronary artery disease	8.82e-07	1.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—coronary artery disease	5.43e-07	6.87e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—coronary artery disease	4.43e-07	5.61e-06	CbGpPWpGaD
